Display options
Cite
Marzola P, Boschi F, Moneta F, et al. Preclinical . Front Pharmacol. 2016;7:336doi: 10.3389/fphar.2016.00336.
Marzola, P., Boschi, F., Moneta, F., Sbarbati, A., & Zancanaro, C. (2016). Preclinical . Frontiers in pharmacology, 7336. https://doi.org/10.3389/fphar.2016.00336
Marzola, Pasquina, et al. "Preclinical ." Frontiers in pharmacology vol. 7 (2016): 336. doi: https://doi.org/10.3389/fphar.2016.00336
Marzola P, Boschi F, Moneta F, Sbarbati A, Zancanaro C. Preclinical . Front Pharmacol. 2016 Sep 26;7:336. doi: 10.3389/fphar.2016.00336. eCollection 2016. PMID: 27725802; PMCID: PMC5035738.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Sep 26;7:336. doi: 10.3389/fphar.2016.00336. eCollection 2016.

Preclinical .

Frontiers in pharmacology

Pasquina Marzola, Federico Boschi, Francesco Moneta, Andrea Sbarbati, Carlo Zancanaro

Affiliations

  1. Department of Computer Science, University of Verona, Verona Italy.
  2. Preclinical Imaging Division - Bruker BioSpin, Bruker Italia s.r.l, Milano Italy.
  3. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona Italy.

PMID: 27725802 PMCID: PMC5035738 DOI: 10.3389/fphar.2016.00336

Abstract

Localization, differentiation, and quantitative assessment of fat tissues have always collected the interest of researchers. Nowadays, these topics are even more relevant as obesity (the excess of fat tissue) is considered a real pathology requiring in some cases pharmacological and surgical approaches. Several weight loss medications, acting either on the metabolism or on the central nervous system, are currently under preclinical or clinical investigation. Animal models of obesity have been developed and are widely used in pharmaceutical research. The assessment of candidate drugs in animal models requires non-invasive methods for longitudinal assessment of efficacy, the main outcome being the amount of body fat. Fat tissues can be either quantified in the entire animal or localized and measured in selected organs/regions of the body. Fat tissues are characterized by peculiar contrast in several imaging modalities as for example Magnetic Resonance Imaging (MRI) that can distinguish between fat and water protons thank to their different magnetic resonance properties. Since fat tissues have higher carbon/hydrogen content than other soft tissues and bones, they can be easily assessed by Computed Tomography (CT) as well. Interestingly, MRI also discriminates between white and brown adipose tissue (BAT); the latter has long been regarded as a potential target for anti-obesity drugs because of its ability to enhance energy consumption through increased thermogenesis. Positron Emission Tomography (PET) performed with

Keywords: BAT; CT imaging; MRI imaging; PET imaging; fat

References

  1. J Lipid Res. 1999 Aug;40(8):1395-400 - PubMed
  2. Curr Opin Clin Nutr Metab Care. 1998 Sep;1(5):439-48 - PubMed
  3. Am J Physiol Endocrinol Metab. 2000 May;278(5):E941-8 - PubMed
  4. Diabetes Metab. 2000 Jun;26 Suppl 3:10-2 - PubMed
  5. Annu Rev Cell Dev Biol. 2000;16:145-71 - PubMed
  6. Eat Weight Disord. 2000 Sep;5(3):132-42 - PubMed
  7. Metabolism. 2001 Apr;50(4):425-35 - PubMed
  8. J Clin Invest. 2001 Oct;108(8):1205-13 - PubMed
  9. Magn Reson Med. 2001 Nov;46(5):879-83 - PubMed
  10. J Nutr. 2001 Nov;131(11):2963-6 - PubMed
  11. Obes Res. 2003 Jan;11(1):5-16 - PubMed
  12. J Clin Densitom. 2003 Summer;6(2):75-85 - PubMed
  13. Physiol Rev. 2004 Jan;84(1):277-359 - PubMed
  14. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56 - PubMed
  15. Am J Physiol Regul Integr Comp Physiol. 2004 Nov;287(5):R1132-40 - PubMed
  16. Diabet Med. 2005 Apr;22(4):359-70 - PubMed
  17. Am J Clin Nutr. 1992 Jul;56(1):19-28 - PubMed
  18. Mil Med. 1992 Apr;157(4):189-92 - PubMed
  19. Magn Reson Med. 2006 Apr;55(4):715-8 - PubMed
  20. Clin Endocrinol (Oxf). 2006 Apr;64(4):355-65 - PubMed
  21. Obesity (Silver Spring). 2006 Mar;14(3):405-14 - PubMed
  22. J Nucl Med. 2006 Jun;47(6):999-1006 - PubMed
  23. NMR Biomed. 2007 May;20(3):154-85 - PubMed
  24. Cell Metab. 2007 May;5(5):371-81 - PubMed
  25. Anat Rec. 1991 Nov;231(3):293-7 - PubMed
  26. PLoS One. 2007 Aug 01;2(8):e683 - PubMed
  27. Int J Obes (Lond). 2008 Feb;32(2):232-8 - PubMed
  28. Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17879-84 - PubMed
  29. Obesity (Silver Spring). 2008 Mar;16(3):600-7 - PubMed
  30. Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1304-10 - PubMed
  31. Med Eng Phys. 2009 Jan;31(1):34-41 - PubMed
  32. J Lipid Res. 2008 Sep;49(9):1894-903 - PubMed
  33. Cell Metab. 2009 Feb;9(2):203-9 - PubMed
  34. Gend Med. 2009;6 Suppl 1:60-75 - PubMed
  35. Methods. 2010 Jan;50(1):14-9 - PubMed
  36. Obes Rev. 2010 Jan;11(1):11-8 - PubMed
  37. Methods. 2010 Jan;50(1):2-13 - PubMed
  38. Obes Rev. 2010 Nov;11(11):792-807 - PubMed
  39. J Magn Reson Imaging. 2010 Jan;31(1):4-18 - PubMed
  40. J Nucl Med. 2010 Feb;51(2):246-50 - PubMed
  41. J Submicrosc Cytol Pathol. 1991 Jan;23(1):167-74 - PubMed
  42. J Lipid Res. 2011 Feb;52(2):330-6 - PubMed
  43. Nat Med. 2011 Feb;17(2):200-5 - PubMed
  44. J Biomed Biotechnol. 2011;2011:197636 - PubMed
  45. Lipids. 2011 Jul;46(7):659-67 - PubMed
  46. Obesity (Silver Spring). 2012 Jan;20(1):30-9 - PubMed
  47. Neuroendocrinology. 2011;94(2):158-68 - PubMed
  48. J Nucl Med. 2011 Oct;52(10):1616-20 - PubMed
  49. J Magn Reson Imaging. 2011 Oct;34(4):729-749 - PubMed
  50. EJNMMI Res. 2011 Dec 01;1(1):30 - PubMed
  51. Magn Reson Med. 2012 Oct;68(4):1285-90 - PubMed
  52. Magn Reson Imaging. 2012 Apr;30(3):323-9 - PubMed
  53. J Clin Invest. 2012 Feb;122(2):545-52 - PubMed
  54. Diabetes. 2012 Mar;61(3):674-82 - PubMed
  55. Obesity (Silver Spring). 2012 Jul;20(7):1519-26 - PubMed
  56. Trends Endocrinol Metab. 2012 Jun;23(6):270-7 - PubMed
  57. MAGMA. 2012 Oct;25(5):381-9 - PubMed
  58. Obesity (Silver Spring). 2012 Jul;20(7):1527-9 - PubMed
  59. J Vis Exp. 2012 Apr 04;(62):e3680 - PubMed
  60. Nucl Med Biol. 2012 Oct;39(7):1081-6 - PubMed
  61. Am J Physiol Endocrinol Metab. 2012 Dec 1;303(11):E1287-95 - PubMed
  62. Synapse. 2013 Feb;67(2):79-93 - PubMed
  63. Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E160-7 - PubMed
  64. J Vis Exp. 2012 Nov 23;(69):null - PubMed
  65. J Magn Reson Imaging. 2013 Dec;38(6):1425-33 - PubMed
  66. Metabolism. 2013 Aug;62(8):1189-98 - PubMed
  67. Mol Cell Endocrinol. 2013 Oct 15;379(1-2):43-50 - PubMed
  68. PLoS One. 2013 Apr 24;8(4):e62007 - PubMed
  69. Int J Obes (Lond). 2014 Jan;38(1):126-31 - PubMed
  70. Cell Metab. 2013 Jun 4;17(6):851-9 - PubMed
  71. NMR Biomed. 2013 Dec;26(12):1663-71 - PubMed
  72. PLoS One. 2013 Sep 10;8(9):e74206 - PubMed
  73. Mol Metab. 2013 Apr 21;2(3):153-60 - PubMed
  74. Nucl Med Biol. 2014 Jan;41(1):10-6 - PubMed
  75. NMR Biomed. 2013 Dec;26(12):1609-29 - PubMed
  76. Int J Obes (Lond). 2014 Aug;38(8):1019-26 - PubMed
  77. NMR Biomed. 2014 Apr;27(4):431-43 - PubMed
  78. Acta Physiol (Oxf). 2014 Apr;210(4):733-53 - PubMed
  79. IEEE J Biomed Health Inform. 2015 Mar;19(2):660-7 - PubMed
  80. PLoS One. 2014 Aug 21;9(8):e105556 - PubMed
  81. Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2217-23 - PubMed
  82. N Engl J Med. 2014 Sep 18;371(12):1131-41 - PubMed
  83. Sensors (Basel). 2014 Oct 08;14(10):18526-42 - PubMed
  84. Rev Endocr Metab Disord. 2014 Dec;15(4):289-98 - PubMed
  85. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):18001-6 - PubMed
  86. PLoS One. 2014 Dec 02;9(12):e113742 - PubMed
  87. Phys Med. 2015 Mar;31(2):120-9 - PubMed
  88. Obesity (Silver Spring). 2015 Mar;23(3):512-8 - PubMed
  89. FASEB J. 2015 May;29(5):2046-58 - PubMed
  90. Nucl Med Biol. 2015 Aug;42(8):691-4 - PubMed
  91. J Mater Chem B. 2015 Mar 7;3(9):1979-1989 - PubMed
  92. Nat Rev Drug Discov. 2016 Jun;15(6):405-24 - PubMed
  93. Am J Physiol Endocrinol Metab. 2016 Jul 1;311(1):E260-8 - PubMed
  94. Radiology. 1984 Oct;153(1):189-94 - PubMed
  95. Biol Cell. 1995;83(2-3):163-7 - PubMed
  96. Int J Obes Relat Metab Disord. 1996 Apr;20(4):346-52 - PubMed
  97. Eur J Clin Nutr. 1996 Nov;50(11):747-52 - PubMed
  98. J Lipid Res. 1997 Feb;38(2):343-7 - PubMed

Publication Types